Arcus Biosciences Inc (NYSE: RCUS) on Friday, soared 4.84% from the previous trading day, before settling in for the closing price of $9.91. Within the past 52 weeks, RCUS’s price has moved between $6.50 and $18.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -10.20% annually for the last half of the decade. The company achieved an average annual earnings per share of -20.20%. With a float of $65.43 million, this company’s outstanding shares have now reached $106.40 million.
In an organization with 627 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 100.0%, operating margin of -129.01%, and the pretax margin is -116.79%.
Arcus Biosciences Inc (RCUS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 38.97%, while institutional ownership is 63.67%. The most recent insider transaction that took place on Feb 27 ’25, was worth 201,200. In this transaction Director of this company bought 20,000 shares at a rate of $10.06, taking the stock ownership to the 28,400 shares. Before that another transaction happened on Feb 27 ’25, when Company’s Chief Executive Officer bought 19,800 for $10.18, making the entire transaction worth $201,465. This insider now owns 2,554,160 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1 earnings per share (EPS) for the period topping the consensus outlook (set at -1.07) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.20% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.99% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 4.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.22.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.17, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.20 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was inferior than the volume of 1.03 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 66.92%.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 91.75%, which indicates a significant increase from 81.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.53 in the past 14 days, which was lower than the 0.54 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.22, while its 200-day Moving Average is $11.26. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $10.61. Second resistance stands at $10.83. The third major resistance level sits at $11.15. If the price goes on to break the first support level at $10.07, it is likely to go to the next support level at $9.75. Assuming the price breaks the second support level, the third support level stands at $9.53.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 1.11 billion based on 106,431K outstanding shares. Right now, sales total 258,000 K and income totals -283,000 K. The company made 160,000 K in profit during its latest quarter, and 0 K in sales during its previous quarter.
